Kurma Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Avidicure is a cancer care company focused on enhancing immune system function through innovative therapies. It is developing a novel antibody modality known as "AVC-Boosters," which are dual agonistic and multifunctional, engineered to deliver targeted and effective monotherapy. This approach aims to provide broad applicability in oncology, addressing various cancer types while prioritizing safety and efficacy. Currently, Avidicure is operating in stealth mode, indicating a focus on research and development before public engagement.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.

Germitec is a healthcare company focused on developing ultraviolet light disinfection systems aimed at improving hospital hygiene. The company specializes in high-level disinfection using UV-C technology, which is designed to effectively reprocess non-lumen medical devices. By simplifying safety protocols and reducing the time and responsibility of healthcare professionals, Germitec's systems help transform clinical practices and minimize the risk of cross-infection within medical facilities.

Hopia is a scheduling solution specifically designed for healthcare institutions, focusing on the optimization of human and material resources. The platform centralizes the management of doctors' and nurses' schedules, employing constrained optimization and prediction algorithms to establish the most efficient organization for all stakeholders involved. By streamlining scheduling processes, Hopia aims to enhance operational efficiency, allowing healthcare personnel to allocate more time to patient care and improve overall service delivery in the healthcare sector.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Omnidoc is a tele-expertise platform focused on enhancing communication among healthcare professionals. It enables the exchange of medical opinions by facilitating phone-based medical verification for patients who qualify for health insurance. The platform serves medical institutions and private physicians by streamlining the process of obtaining informal medical opinions, strengthening connections between primary and specialized care providers, and centralizing requests from correspondents. Additionally, it allows users to identify and connect with doctors and healthcare organizations, thereby improving the quality and security of the opinions exchanged. Omnidoc also automates several administrative tasks, contributing to a more efficient healthcare experience for both providers and patients.

Raidium is a Medtech startup that is developing the first-ever radiological foundation model, as the “GPT-4” of radiology. This new generation of AI will enable the building of an imaging biomarker factory for both clinical practice and research, to tackle the complexity of precision medicine.

PanTera focuses on the large-scale production of actinium-225, a promising radioisotope for targeted cancer therapies. The company aims to improve accessibility to personalized nuclear medicine treatments while ensuring sustainability through the recycling of materials in their production process.

SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs specifically for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product lineup includes SH-111, a sterile injectable solution for treating T-cell leukemia in both pediatric and adult patients, and SH-105, another oncology drug. Through its offerings, Shorla Pharma seeks to make a significant impact on patient care and improve clinical outcomes in the oncology sector.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Axithra is a company that specializes in therapeutic medication monitoring, specifically focusing on beta-lactam antibiotics. The business has developed a platform that enables rapid and accurate measurement of drug concentrations in the bloodstream, which is essential for personalized treatment in intensive care settings. By utilizing proprietary optical and photonics technology, Axithra's application allows healthcare providers to tailor antibiotic treatments to the individual needs of patients. This innovation aims to enhance patient care by ensuring that drug levels are monitored effectively, facilitating prompt adjustments to optimize therapeutic outcomes.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Charles helps men regain control over their daily health concerns by starting with their personal health.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a breakthrough discovery that identifies CXCR4 as a master regulator of inflammation. This research underpins the development of therapies that aim to control interferons through plasmacytoid dendritic cells. Ermium Therapeutics has secured a worldwide exclusive license for its intellectual property from CNRS and the University of Paris Descartes, facilitated by an agreement with Erganeo, which has supported the project's academic maturation. The company has gained recognition for its work, notably receiving the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Germitec is a healthcare company focused on developing ultraviolet light disinfection systems aimed at improving hospital hygiene. The company specializes in high-level disinfection using UV-C technology, which is designed to effectively reprocess non-lumen medical devices. By simplifying safety protocols and reducing the time and responsibility of healthcare professionals, Germitec's systems help transform clinical practices and minimize the risk of cross-infection within medical facilities.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

Damae Medical is a medtech company based in Paris, France, specializing in innovative imaging technology for the medical field. The company has developed a device that allows for in-vivo imaging of biological tissues at a cellular level. This technology enables dermatologists to assess the malignancy of tumors quickly and efficiently through simple contact with the skin's surface, eliminating the need for tissue excision and processing. By providing cellular-resolution imaging similar to traditional histology, Damae Medical aims to enhance skin cancer diagnosis and facilitate immediate, non-invasive assessments for healthcare professionals. The company's mission focuses on leveraging bio-photonics to create new opportunities in medical imaging and diagnostics.

NaoX Technologies is focused on preventing neurological disorders through innovative connected solutions. The company has developed wireless headphones equipped with integrated sensors that passively monitor brain activity by detecting brain vibrations. These headphones record electroencephalogram data in real time and aggregate the information on a software dashboard for healthcare professionals. By providing this technology, NaoX Technologies aims to democratize access to neurological disorder prevention and support patients in their recovery from mental health issues.

ARMGO Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics aimed at treating debilitating cardiac, skeletal muscular, and neurological disorders. The company's primary product, Rycals, functions as calcium release channel stabilizers that target the ryanodine receptor/calcium release channel found on the sarcoplasmic/endoplasmic reticulum of cells. This innovative approach addresses conditions such as chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, ARMGO Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Omnidoc is a tele-expertise platform focused on enhancing communication among healthcare professionals. It enables the exchange of medical opinions by facilitating phone-based medical verification for patients who qualify for health insurance. The platform serves medical institutions and private physicians by streamlining the process of obtaining informal medical opinions, strengthening connections between primary and specialized care providers, and centralizing requests from correspondents. Additionally, it allows users to identify and connect with doctors and healthcare organizations, thereby improving the quality and security of the opinions exchanged. Omnidoc also automates several administrative tasks, contributing to a more efficient healthcare experience for both providers and patients.

Arkhn is a company focused on healthcare data interoperability, addressing challenges related to accessing and managing healthcare data. It develops medical enterprise software that standardizes healthcare information to enhance patient care and support medical teams. By improving data accessibility, Arkhn aims to facilitate medical research and innovation while streamlining the operations of healthcare centers. This enables healthcare establishments to provide better support for patients and caregivers, ultimately accelerating advancements in the healthcare sector.

SmartCatch specializes in liquid biopsy technology aimed at enhancing cancer detection and treatment. The company has developed a minimally invasive method to extract circulating tumor cells, offering a series of products focused on the capture and isolation of these cells. This technology provides researchers and clinicians with valuable data that can significantly improve cancer patient outcomes. By empowering the medical community with advanced tools, SmartCatch contributes to the ongoing battle against cancer, facilitating better diagnostic and therapeutic approaches.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Argobio is a start-up studio focused on developing innovative therapeutic solutions and fostering the growth of biotech firms. It collaborates with leading European academic research institutes to identify and nurture early-stage projects, particularly in the areas of rare diseases, neurological disorders, oncology, and immunology. By providing financial support and operational expertise, Argobio aims to cultivate these projects before launching them as independent companies. The studio also seeks to create promising platform technologies that can lead to new therapeutic products, thereby enhancing the drug research and development process for startups in the biotechnology sector.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.

Corlieve Therapeutics SAS is a biotechnology company based in Paris, France, dedicated to developing innovative therapeutic options for patients suffering from severe neurological disorders. The company's primary focus is on addressing temporal lobe epilepsy (TLE) through a gene therapy approach that targets aberrantly expressed kainate receptors in the hippocampus. This lead project is grounded in research from notable institutions, including INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. Established in 2019, Corlieve Therapeutics aims to improve the quality of life for patients with refractory TLE by offering new therapeutic solutions.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.

Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a breakthrough discovery that identifies CXCR4 as a master regulator of inflammation. This research underpins the development of therapies that aim to control interferons through plasmacytoid dendritic cells. Ermium Therapeutics has secured a worldwide exclusive license for its intellectual property from CNRS and the University of Paris Descartes, facilitated by an agreement with Erganeo, which has supported the project's academic maturation. The company has gained recognition for its work, notably receiving the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative therapies for premenstrual dysphoric disorder (PMDD) and other menstrually related conditions. The company is advancing Sepranolone (UC1010), a treatment specifically targeting PMDD, and is also working on a second-generation oral compound currently in preclinical development for the same disorder. Asarina's research is grounded in over 40 years of study into allopregnanolone-related neurological disorders, and it aims to create a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These compounds are intended to provide effective and safe treatment options for a range of neuroendocrinological conditions that remain largely untreated.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Damae Medical is a medtech company based in Paris, France, specializing in innovative imaging technology for the medical field. The company has developed a device that allows for in-vivo imaging of biological tissues at a cellular level. This technology enables dermatologists to assess the malignancy of tumors quickly and efficiently through simple contact with the skin's surface, eliminating the need for tissue excision and processing. By providing cellular-resolution imaging similar to traditional histology, Damae Medical aims to enhance skin cancer diagnosis and facilitate immediate, non-invasive assessments for healthcare professionals. The company's mission focuses on leveraging bio-photonics to create new opportunities in medical imaging and diagnostics.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative therapies for premenstrual dysphoric disorder (PMDD) and other menstrually related conditions. The company is advancing Sepranolone (UC1010), a treatment specifically targeting PMDD, and is also working on a second-generation oral compound currently in preclinical development for the same disorder. Asarina's research is grounded in over 40 years of study into allopregnanolone-related neurological disorders, and it aims to create a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These compounds are intended to provide effective and safe treatment options for a range of neuroendocrinological conditions that remain largely untreated.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.